US 12,110,560 B2
Methods for monitoring residual disease
AmirAli Talasaz, Atherton, CA (US)
Assigned to Guardant Health, Inc., Palo Alto, CA (US)
Filed by GUARDANT HEALTH, INC., Palo Alto, CA (US)
Filed on Mar. 4, 2024, as Appl. No. 18/594,336.
Application 18/594,336 is a continuation of application No. 18/333,436, filed on Jun. 12, 2023.
Application 18/333,436 is a continuation of application No. 17/696,524, filed on Mar. 16, 2022, granted, now 11,879,158, issued on Jan. 23, 2024.
Application 17/696,524 is a continuation of application No. 17/386,338, filed on Jul. 27, 2021, granted, now 11,319,598, issued on May 3, 2022.
Application 17/386,338 is a continuation of application No. 17/370,941, filed on Jul. 8, 2021, granted, now 11,319,597, issued on May 3, 2022.
Application 17/370,941 is a continuation of application No. 17/210,191, filed on Mar. 23, 2021.
Application 17/210,191 is a continuation of application No. 16/709,437, filed on Dec. 10, 2019, granted, now 10,961,592, issued on Mar. 30, 2021.
Application 16/709,437 is a continuation of application No. 16/593,633, filed on Oct. 4, 2019, granted, now 10,822,663, issued on Nov. 3, 2020.
Application 16/593,633 is a continuation of application No. 16/575,128, filed on Sep. 18, 2019, granted, now 10,793,916, issued on Oct. 6, 2020.
Application 16/575,128 is a continuation of application No. 16/283,635, filed on Feb. 22, 2019, granted, now 10,494,678, issued on Dec. 3, 2019.
Application 16/283,635 is a continuation of application No. 15/872,831, filed on Jan. 16, 2018, granted, now 10,457,995, issued on Oct. 29, 2019.
Application 15/872,831 is a continuation of application No. 15/828,099, filed on Nov. 30, 2017, granted, now 10,837,063, issued on Nov. 17, 2020.
Application 15/828,099 is a continuation of application No. 15/467,570, filed on Mar. 23, 2017, granted, now 9,840,743, issued on Dec. 12, 2017.
Application 15/467,570 is a continuation of application No. 14/425,189, granted, now 10,041,127, issued on Aug. 7, 2018, previously published as PCT/US2013/058061, filed on Sep. 4, 2013.
Claims priority of provisional application 61/845,987, filed on Jul. 13, 2013.
Claims priority of provisional application 61/793,997, filed on Mar. 15, 2013.
Claims priority of provisional application 61/704,400, filed on Sep. 21, 2012.
Claims priority of provisional application 61/696,734, filed on Sep. 4, 2012.
Prior Publication US 2024/0200150 A1, Jun. 20, 2024
Int. Cl. C12Q 1/68 (2018.01); C12N 15/10 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6886 (2018.01); G16B 30/00 (2019.01); G16B 30/10 (2019.01)
CPC C12Q 1/6886 (2013.01) [C12N 15/1065 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6874 (2013.01); G16B 30/00 (2019.02); G16B 30/10 (2019.02); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01)] 20 Claims
 
1. A method for monitoring residual disease in a subject, the method comprising:
(a) providing a first sample from the subject comprising genomic polynucleotides and sequencing the genomic polynucleotides or amplicons thereof to generate a first set of sequence data, wherein the first sample is obtained from a tumor biopsy from the subject;
(b) determining a frequency of cancer mutations from the first set of sequence data from the first sample;
(c) providing a second sample from the subject comprising cell-free deoxyribonucleic acid (cfDNA) molecules and sequencing the cfDNA molecules or amplicons thereof to produce a second set of sequence data, wherein the second sample is obtained from the subject after the subject has undergone a course of treatment for cancer;
(d) determining a frequency of the cancer mutations discovered in the first sample from the second set of sequence data from the second sample; and
(e) determining a presence or absence of cancer in the subject based on an analysis of the frequency of the cancer mutations from the second set of sequence data from the second sample, thereby monitoring for the residual disease in the subject.